MBSHPHA@EC2610A

Shanghai Pharmaceuticals' New Generation Direct Renin Inhibitor Enters Clinical Application

Shanghai Pharmaceutical's Subsidiary Qingchunbao Receives Clinical Trial Approval for Seven-Ingredient Fangji Huangqi Granules

Shanghai Pharmaceutical Obtains Registration Certificate for Pyridostigmine Bromide Oral Solution

Shanghai Pharmaceutical Smart Supply Chain Technology Co., Ltd. Established with a Registered Capital of 20 Million Yuan

Shanghai Pharmaceutical's Subsidiary's Sotalol Hydrochloride Tablets Pass Consistency Evaluation

Description of 2025 China Enterprise Science and Technology Innovation Power Ranking in Wholesale and Retail Industry

Shanghai Pharmaceutical Terminates Cooperation Agreement with Shengnuo Biotechnology for Novel Acid Inhibitor X842

Shanghai Pharmaceutical Subsidiary's Tramadol Hydrochloride Injection Passes Consistency Evaluation

HSBC Research Maintains Ratings for Shanghai Pharmaceuticals and Sinopharm with Target Price Adjustments

Shanghai Pharmaceuticals Subsidiary's Eslicarbazepine Acetate ANDA Approved by FDA

Shanghai Pharmaceutical Subsidiary Obtains Registration Certificate for Tofacitinib Citrate Extended-Release Tablets

Shanghai Pharmaceuticals Subsidiary's Ticagrelor Tablets Approved by FDA for US Market

Citibank Downgrades Shanghai Pharmaceuticals' Revenue Forecast But Raises Target Price

UBS Publishes Report Analyzing Shanghai Pharmaceutical's Performance and Future Outlook

SH PHARMA released FY2025 Q3 earnings on October 30 After-Market (BJT), actual revenue HKD 80.33 B (forecast HKD 79.24 B), actual EPS HKD 0.2037 (forecast HKD 0.306)

SH PHARMA released FY2025 9 Months earnings on October 30 After-Market (BJT), actual revenue HKD 233.64 B, actual EPS HKD 1.5079

Shanghai Pharmaceutical Subsidiary Receives Approval to Produce Pyridostigmine Bromide Extended-Release Tablets

Shanghai ShangPharma Zhongxi Amisulpride Orally Disintegrating Tablets Holder Change Approved

SH PHARMA to Release FY2025 Q3 Earnings on October 30 After-Market (BJT), Forecast Revenue HKD 79.25 B, EPS HKD 0.306

Shanghai Pharmaceutical's Rivaroxaban Tablets Obtain Approval from Malaysia's Regulatory Authority

TIMES UNI GP

CENTURY GINWA

STARGLORY HLDGS

RIDGE OUTDOOR

SYNAGISTICS

PROSP INV HOLD

HING LEE (HK)

ELEGANCEOPTICAL

CH ENV TECH&BIO

SHANGHAI QINGPU

512290

000037

02607

601607

588860

588130

589720

588250

Shanghai Pharmaceuticals Holding Co. Ltd. has elected Mr. Zhao Yong as the employee director of its eighth board. His term will commence immediately and continue until the end of the board's eighth session. This announcement was published via the Issuer Information Service of the Hong Kong Stock Exchange.

Reuters

Guotai CSI Bio-medicine ETF

SSE Health Care

SH PHARMA

Shanghai Pharma

ICBCCS SSE STAR Biology and Medicine ETF

ChinaAMC SSE STAR Biology and Medicine ETF

Guotai SSE STAR Brand Name Drug ETF

Penghua SSE STAR Biology and Medicine ETF

Shanghai Pharmaceuticals Appoints Zhao Yong as Employee Director

600196

02196

Shanghai Fosun Pharmaceutical Group Co Ltd :DRUG REGISTRATION APPLICATION OF TETRACAINE HYDROCHLORIDE GEL ACCEPTED BY CHINA'S NMPA

FOSUN PHARMA

Shanghai Fosun Pharma Says Drug Registration Application Of Tetracaine Hydrochloride Gel Accepted By NMPA

01530

Results from a Phase 2 trial reveal promising findings for patients who cannot undergo standard reperfusion therapies. This data was presented at the International Stroke Conference and highlights the efficacy of LT3001 in providing significant functional improvements for patients with disabling Acute Ischemic Stroke (AIS). The trial showcased that LT3001 delivers meaningful outcomes for patients ineligible for standard treatments.

Unusual Whales

3SBIO

Breakthrough trial LT3001 shows functional improvement in patients with acute ischemic stroke, ineligible for standard therapies. Presented at conference.

Shanghai Pharmaceuticals Gets Registration Certificate for Sitagliptin/Metformin Tablets

marketscreener

ChinaAMC SSE Health Care ETF Initiating Fund

E Fund Hang Seng SCHK Innovative Drug ETF

China Universal 800 Health Care ETF

Founder Fubon CSI Medicine and Medical Device Innovation ETF

E Fund CSI 300 Health Care ETF

Minsheng Royal CSI Biotechnology Theme ETF

GF CSI All Share Health Care ETF

Hwabao WP Hang Seng SCHK Innovative Drug Select ETF

Bosera Hang Seng SCHK Innovative Drug Select ETF

E Fund CSI Biotechnology Theme ETF

Ping An CSI Medicine and Medical Device Innovation ETF

Tianhong CNI BIOMEDICINE ETF

Fullgoal Hang Seng SCHK Innovative Drug & Healthcare ETF

Yinhua CSI Innovative Drugs Industry ETF

China Merchants CSI Biotechnology Theme ETF

Shanghai Pharmaceuticals Gets Registration Certificate for Sitagliptin/Metformin Tablets

Beijing launched a pilot program for online diagnosis and treatment services on January 31, starting with three pediatric subspecialties at Beijing Children's Hospital and Capital Institute of Pediatrics. This service provides online pre-consultation, online diagnosis and treatment, and medication delivery for first-time patients, aiming to ensure the safety and quality of diagnosis and treatment. Doctors can complete the initial diagnosis and issue prescriptions via the internet

Wallstreetcn

SINOPHARM

CHINARES PHARMA

ChinaAMC CSI All Share Health Care Devices ETF

China Merchants CSI All Share Medical Apparatus and Instruments ETF

ALI HEALTH

JD HEALTH

Maxwealth CSI All Share Medical Apparatus and Instruments ETF

PA GOODDOCTOR

Dacheng CSI All Share Health Care Equipment and Services ETF

SINOPHARM(CNCM LTD)

This afternoon, appointment reservations opened for the pilot program of internet diagnosis and treatment in Beijing

Shanghai Pharmaceuticals' Unit Gets Nod for B023 Cell Injection Trial

China Southern Hang Seng Biotech ETF(QDII)

GF CSI HK Innovative Drugs Industry ETF(QDII)

Huaan Hang Seng Biotech ETF

ChinaAMC Hang Seng Biotechnology Technology ETF(QDII)

Yinhua CSI Research Sector 100 ETF

Shanghai Pharmaceuticals' Unit Gets Nod for B023 Cell Injection Trial

HSBC Research pointed out that the Chinese pharmaceutical industry lacks short-term catalysts, the market recovery is weak, and policies are affecting industry growth. Shanghai Pharma and Sinopharm maintain a "Hold" rating, with target prices lowered to RMB 11.8 and RMB 19.5, respectively. It is expected that the lagging consumption recovery and tightening policies will continue to suppress the industry's short-term upside potential

AASTOCKS

HSBC Research: The domestic pharmaceutical industry lacks short-term catalysts, and the target price for Shanghai Pharma and China National Pharmaceutical Group is lowered

Shanghai Pharma (2607.HK) has recently shown weak price consolidation, remaining in a wait-and-see range overall. The daily MACD continues to show a death cross, and the main moving averages are still under pressure, indicating a cautious attitude in capital flow. The pharmaceutical sector lacks strong policy catalysts in the short term, combined with low market risk appetite, leading to a wait-and-see approach from major players. The company's fundamentals are relatively resilient, but increased competitive pressure and periodic policy regulation in the industry have resulted in limited performance growth elasticity. The technical bottom has not yet solidified, and the trading volume remains persistently low, indicating that major funds have not yet flowed in on a large scale. If there are significant policy benefits or industry event catalysts, short-term funds may react, driving a rapid rebound in stock prices. However, in the absence of clear positive factors, it is recommended that investors focus on controlling positions and defense, paying attention to intraday trading anomalies and changes in capital flow direction, and waiting for opportunities to act

Technical Forecast

Morning Trend | Shanghai Pharma remains weak and cautious, when will it welcome policy catalysts?

UBS raised the target price for Shanghai Pharma to HKD 15, with a rating of "Buy." Management stated that in 2025, they will focus on the business transformation of the industrial and commercial sectors, with the former concentrating on innovative drugs and traditional Chinese medicine, and the latter focusing on CSO and innovative drug services. Although the earnings per share forecast for 2025 was raised by 7%, the earnings forecasts for 2026 and 2027 were lowered by 11% and 10%, respectively. In the first three quarters, operating revenue increased by 2.6% year-on-year, and net profit attributable to the parent company increased by 27%

Zhitong

UBS: Raises target price for Shanghai Pharma to HKD 15, rating "Buy"

Citi has lowered its revenue forecast for Shanghai Pharma for the years 2025 to 2027 by 3% to 6% to reflect the ongoing pressure on core business, and has reduced its earnings per share forecast for the same period by 12% to 14%. However, the bank has raised its target price for Shanghai Pharma from RMB 13.1 to RMB 14.2, as the market may underestimate the long-term value created by the company's manufacturing platform strategic restructuring, the huge potential of the commercial insurance market, and the clear progress in cost optimization; maintaining a "Buy" rating

Citigroup raises the target price of Shanghai Pharma to 14.2 yuan, maintaining a "Buy" rating

Shanghai Pharma released its third-quarter report for 2025, achieving operating revenue of 215.072 billion yuan from January to September 2025, a year-on-year increase of 2.60%. The net profit attributable to the parent company was 5.147 billion yuan, a year-on-year increase of 26.96%. The sales revenue of the pharmaceutical industry was 18.164 billion yuan, a year-on-year decrease of 0.66%; the sales revenue of the pharmaceutical business was 196.908 billion yuan, a year-on-year increase of 2.91%. After deducting one-time special gains and losses, the net profit attributable to the parent company was 3.979 billion yuan, a year-on-year decrease of 1.85%. The net cash flow from operating activities was 2.350 billion yuan, continuing to maintain high-quality development

Shanghai Pharma released its performance for the first three quarters, with a net profit attributable to the parent company of 5.147 billion yuan, a year-on-year increase of 26.96%

MBSHPHA@EC2610A(18734.HK)

Shanghai Pharmaceuticals Appoints Zhao Yong as Employee Director

Shanghai Fosun Pharma Says Drug Registration Application Of Tetracaine Hydrochloride Gel Accepted By NMPA

Breakthrough trial LT3001 shows functional improvement in patients with acute ischemic stroke, ineligible for standard therapies. Presented at conference.

Shanghai Pharmaceuticals Gets Registration Certificate for Sitagliptin/Metformin Tablets

This afternoon, appointment reservations opened for the pilot program of internet diagnosis and treatment in Beijing